Cyfendus market set for faster growth as anthrax preparedness spending rises

The global Cyfendus vaccine market is gaining momentum as governments step up biodefense planning and anthrax preparedness. The Business Research Company says higher healthcare spending, post-exposure prophylaxis demand and stockpiling are set to support growth through the forecast period.

Why it matters: - Cyfendus is used to help protect against anthrax after possible exposure, making it part of public health and biodefense planning. - Rising anthrax concerns, emergency preparedness spending and vaccine stockpiling are expanding the market’s potential demand base.

What happened: - The Business Research Company released a new global Cyfendus market report on Nov. 2, 2026. - The report says the Cyfendus market has grown on the back of bioterrorism preparedness efforts, responses to prior anthrax outbreaks, government-backed vaccine programs, adjuvanted vaccine development and military immunization requirements. - The report says future growth will be driven by biodefense investment, broader emergency response networks, higher public health funding, better vaccine manufacturing and international security cooperation. - The report identifies stronger biodefense vaccine demand, more post-exposure prophylaxis use, government anthrax vaccine stockpiling, greater use of vaccines with antibiotics and stronger national emergency preparedness plans as key trends.

The details: - Cyfendus is a branded intramuscular vaccine formulated to prevent anthrax infection caused by Bacillus anthracis, especially after exposure. - The vaccine contains anthrax vaccine adsorbed and adjuvanted to stimulate protective antibodies. - Cyfendus is typically given with antibiotics as part of post-exposure prophylaxis. - The report says rising anthrax incidence is a major growth driver. - The report ties the increase to closer human-animal contact in endemic areas, environmental disruptions that release spores from soil and limited livestock vaccination coverage. - Zambia reported 684 suspected human anthrax cases, including four deaths, in November 2023, with Sinazongwe district particularly affected. - The report says higher healthcare investment is also supporting the market by funding vaccine development, regulatory approval and distribution. - The UK’s healthcare expenditure reached about £317 billion in 2024, up 6.5% from the prior year, according to the Office for National Statistics. - In 2025, North America held the largest share of the Cyfendus market. - The Asia-Pacific region is expected to be the fastest-growing market during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company said its 2026 market reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and key technology and future trend analysis. - More information is available in the sample report and the full market report.

Between the lines: - The report points to a market shaped less by routine consumer demand and more by government readiness, public health security and emergency stockpiling. - Anthrax outbreaks and biodefense planning appear to be the main force behind demand, which makes the market highly dependent on policy and procurement cycles.

What's next: - The market is expected to keep expanding as governments invest more in biodefense, emergency response capacity and vaccine readiness. - Asia-Pacific may narrow the gap with North America if healthcare infrastructure and biodefense spending keep rising. - The report’s added analytics tools suggest the market is drawing more attention from investors and strategic planners.